Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Spillane

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
JAMA Dermatology|April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous MelanomaSerigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
Nature Medicine|February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaE A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Nature|May 4, 2017
Whole-genome landscapes of major melanoma subtypesNicholas K Hayward, James S Wilmott, Nicola Waddell, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
JAMA Dermatology|April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous MelanomaSerigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
Nature Medicine|February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaE A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Nature|May 4, 2017
Whole-genome landscapes of major melanoma subtypesNicholas K Hayward, James S Wilmott, Nicola Waddell, et al.
Pageof 23